title: A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.
abstract: Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growth factor receptor therapy has revolutionized the treatment of advanced colorectal cancer. This has resulted in the urgent demand for KRAS mutation testing in the clinical setting to aid choice of therapy. The aim of this study was to evaluate six different KRAS mutation detection methodologies on two series of primary colorectal cancer samples. Two series of 80 frozen and 74 formalin-fixed paraffin-embedded tissue samples were sourced and DNA was extracted at a central site before distribution to seven different testing sites. KRAS mutations in codons 12 and 13 were assessed by using single strand conformation polymorphism analysis, pyrosequencing, high resolution melting analysis, dideoxy sequencing, or the commercially available TIB Molbiol (Berlin, Germany) or DxS Diagnostic Innovations (Manchester, UK) kits. In frozen tissue samples, concordance in KRAS status (defined as consensus in at least five assays) was observed in 66/80 (83%) cases. In paraffin tissue, concordance was 46/74 (63%) if all assays were considered or 71/74 (96%) using the five best performing assays. These results demonstrate that a variety of detection methodologies are suitable and provide comparable results for KRAS mutation analysis of clinical samples.
authors.affiliation: Queensland Institute of Medical Research, Bancroft Building, 300 Herston Road, Herston Queensland 4029, Australia. Vicki.Whitehall@qimr.edu.au
authors.forename: Vicki
authors.initials: V
authors.lastname: Whitehall
authors.forename: Kayla
authors.initials: K
authors.lastname: Tran
authors.forename: Aarti
authors.initials: A
authors.lastname: Umapathy
authors.forename: Fabienne
authors.initials: F
authors.lastname: Grieu
authors.forename: Chelsee
authors.initials: C
authors.lastname: Hewitt
authors.forename: Tiffany-Jane
authors.initials: TJ
authors.lastname: Evans
authors.forename: Tuty
authors.initials: T
authors.lastname: Ismail
authors.forename: Wei Qi
authors.initials: WQ
authors.lastname: Li
authors.forename: Peter
authors.initials: P
authors.lastname: Collins
authors.forename: Paul
authors.initials: P
authors.lastname: Ravetto
authors.forename: Barbara
authors.initials: B
authors.lastname: Leggett
authors.forename: Manuel
authors.initials: M
authors.lastname: Salto-Tellez
authors.forename: Richie
authors.initials: R
authors.lastname: Soong
authors.forename: Stephen
authors.initials: S
authors.lastname: Fox
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Scott
authors.forename: Alexander
authors.initials: A
authors.lastname: Dobrovic
authors.forename: Barry
authors.initials: B
authors.lastname: Iacopetta
mesh_terms: D003062:Codon / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods*; D006801:Humans; D066298:In Vitro Techniques; D018807:Polymorphism, Single-Stranded Conformational / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: D003062:Codon; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins